NVRO vs. MDXG, ATRC, AORT, CATX, SILK, ATRI, KIDS, EMBC, FNA, and PLSE
Should you be buying Nevro stock or one of its competitors? The main competitors of Nevro include MiMedx Group (MDXG), AtriCure (ATRC), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), Paragon 28 (FNA), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
MiMedx Group (NASDAQ:MDXG) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 1.3% of MiMedx Group shares are owned by insiders. Comparatively, 3.2% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Nevro had 3 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Nevro and 3 mentions for MiMedx Group. Nevro's average media sentiment score of 1.12 beat MiMedx Group's score of -0.39 indicating that MiMedx Group is being referred to more favorably in the media.
MiMedx Group has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
MiMedx Group has a net margin of 18.63% compared to MiMedx Group's net margin of -19.17%. Nevro's return on equity of 39.42% beat MiMedx Group's return on equity.
Nevro received 469 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.27% of users gave MiMedx Group an outperform vote while only 65.75% of users gave Nevro an outperform vote.
MiMedx Group currently has a consensus target price of $12.25, suggesting a potential upside of 63.12%. Nevro has a consensus target price of $19.46, suggesting a potential upside of 104.43%. Given MiMedx Group's higher possible upside, analysts clearly believe Nevro is more favorable than MiMedx Group.
MiMedx Group has higher earnings, but lower revenue than Nevro. Nevro is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Summary
MiMedx Group beats Nevro on 12 of the 18 factors compared between the two stocks.
Get Nevro News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
